New results released today point the way toward a potential new Alzheimer’s disease therapy, which will soon be trialled in Australia’s major cities.
If you are over 65 and noticed that your memory is declining, or you are newly diagnosed with dementia, you can register your interest in being involved in the study at 3D@florey.edu.au. Eligible participants will be contacted when the study opens for enrolment later this year.
A collaboration between researchers at the Florey and CSIRO led have shown an association between higher levels of brain iron, the presence of the Alzheimer’s protein, amyloid, and poorer memory and language skills.
Dr Scott Ayton and Professor Ashley Bush from the Florey Institute of Neuroscience and Mental Health and CRC for Mental Health led the study, published today in Brain, which used the data gathered from 117 participants in the Australian Imaging and Biomarker lifestyle (AIBL) study.
Scientists have long known that the slow build-up of a substance known as amyloid in the brain determines whether people will eventually experience Alzheimer’s disease. The team of Australian researchers have shown that about 30 per cent of people in their 70s have high levels of amyloid in their brain, but confusingly, some retain all their cognitive faculties much longer than others. Some other factor had to be involved. It turns out, that something else may be iron.
Six years ago, 117 AIBL participants had their levels of amyloid protein and brain iron measured using brain scans – PET for amyloid and MRI for iron. Every 18 months since, their memory, language, attention and executive functioning has been exhaustively tested. The researchers used this data to see whether brain iron and amyloid can predict people’s cognitive performance.
The Florey’s Dr Ayton says, “Cognitive abilities like short-term memory, executive function and language ability declined much faster in people with high brain iron levels and high amyloid levels, even if they were otherwise healthy, than those with low brain iron who were also amyloid positive.”
Although this study used correlations between iron, amyloid and cognitive performance, and thus iron can’t yet be called a ‘causative’ agent in Alzheimer’s disease, the results make compelling biological sense. Higher iron levels in the hippocampus of amyloid-positive people predicted worse performance on a series of short-term memory tasks. The hippocampus, curiously enough, is where our short-term memories are created and stored. Similarly, our powers of language are mainly centred in our temporal lobe (just above where our ears sit) and our frontal lobe, and higher iron in these brain regions predicted poorer performance in language-based tasks.
“These results suggest that iron acts together with amyloid to speed up the Alzheimer’s disease process. Those individuals with high amyloid but low iron will also eventually go on to develop Alzheimer’s disease, but much later than their high-iron counterparts” says Dr Ayton.
The discovery was made possible using technology developed by CSIRO and conducted in a collaborative study funded by the CRC for Mental Health. “We’ve refined MRI technology to allow the very precise mapping of iron levels in the brain,” said CSIRO researcher Dr Olivier Salvado, one of the lead authors of the paper. “Collaborating with world-leading scientists at the Florey Institute was critical to drive our innovation into potential clinical use.”
The researchers are excited by the study, because it opens up a promising new avenue for Alzheimer’s drug treatments.
To test the theory, Florey scientists plan to use an existing drug, deferiprone, to ‘mop-up’ excess iron in the brain and see if it can slow down the progression of the disease.
“The 3D trial is extremely exciting because for the first time we will able to assess someone's risk of progressing into cognitive decline without needing to perform invasive and costly tests. We will also be testing a compound that may prevent or slow the natural course of the disease” says Professor Bush. “If the 3D trial results prove that low iron slows disease progression, we imagine a future where your GP sends you off for your 60-year health check, including a brain iron MRI scan, which is quick, cheap and painless. If you have high brain iron, then we would order an amyloid PET scan. Once we had those two measurements, we could predict the likely onset of Alzheimer’s and begin you on therapy to lower the iron, and delay disease onset.”
Dr Thomas Keeble
Neuroscience Communications and Media
Watch Professor Bush and Dr Ayton discuss the important role iron plays in the Alzheimer's disease process:
The Florey Institute of Neuroscience and Mental Health is the largest brain research group in the Southern Hemisphere. Our teams work on a range of serious diseases including stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, motor neurone disease, traumatic brain and spinal cord injury, depression, schizophrenia, mental illness and addiction. We are world leaders in imaging technology, stroke rehabilitation and epidemiological studies. Research of the brain and its diseases has gained considerable momentum internationally. Many scientific and technological advancements have been made, and much of our work has been centre stage. Our scientific home is a hive of activity with researchers coming from around the globe to work at the Florey. State and Federal Governments, major philanthropic foundations and many generous private benefactors have recognised the importance of neuroscience as the final frontier in medical research.
At CSIRO, we do the extraordinary every day. We innovate for tomorrow and help improve today – for our customers, all Australians and the world. We imagine. We collaborate. We innovate.